Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.49
-0.11 (-1.45%)
Nov 28, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Revenue
Cartesian Therapeutics had revenue of $452.00K in the quarter ending September 30, 2025, with 16.80% growth. This brings the company's revenue in the last twelve months to $1.09M, down -97.72% year-over-year. In the year 2024, Cartesian Therapeutics had annual revenue of $38.91M with 49.64% growth.
Revenue (ttm)
$1.09M
Revenue Growth
-97.72%
P/S Ratio
177.31
Revenue / Employee
$16,530
Employees
66
Market Cap
194.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38.91M | 12.91M | 49.64% |
| Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
| Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
| Dec 31, 2021 | 85.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAC News
- 13 days ago - Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis - Seeking Alpha
- 4 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 3 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Cartesian (RNAC) Q2 Revenue Drops 99% - The Motley Fool
- 6 months ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire
- 7 months ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire